RxDoctor Payments Data

Ryan Bonek, MD

Family Medicine · Mishawaka, INNPI 1730523846

Payments from drug & device makers

$2,718in general payments, 2019–2025

Across 156 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$442
  • Lilly USA, LLC$397
  • AbbVie$335
  • AstraZeneca$306
  • Pfizer$291
  • Amgen$130
  • plus $816 from 22 others

What the payments were for

  • Food & beverage$2,67398%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,718 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$66,705
Medicare patients
172
Services billed
12,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$93,336
OzempicSemaglutide58$74,012
TrulicityDulaglutide57$68,141
MounjaroTirzepatide65$68,120
EliquisApixaban65$56,287
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$44,354
XareltoRivaroxaban15$22,553
JanuviaSitagliptin Phosphate20$17,844
RybelsusSemaglutide13$11,944
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$9,733
Tresiba Flextouch U-200Insulin Degludec14$7,535
BelsomraSuvorexant15$6,216
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,041
Atorvastatin Calcium439$3,340
Levothyroxine Sodium273$2,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$397$136,261122 claims
Boehringer IngelheimJardiance$93$93,33679 claims
Novo NordiskOzempic, Rybelsus$442$85,95671 claims
PfizerEliquis$291$56,28765 claims
GSKTrelegy Ellipta$28$44,35454 claims
MerckJanuvia, Belsomra$65$24,06035 claims
Johnson & JohnsonXarelto$12$22,55315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →